No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - ValiRx, a life science company focussed on early-stage cancer therapeutics and women's health, announced the first sale from its wholly-owned subsidiary Inaphaea BioLabs on Monday.
The AIM-traded firm said the shipment included patient-derived cells (PDCs), part of Inaphaea's new Assay Ready Reagents (ARR) product line.
It said the ARR range allowed customers to perform assays directly without requiring in-house cell cultivation, streamlining research workflows.
While the financial value of the initial order was said to not be material, the board said the sale represented a key milestone in validating Inaphaea's offering and providing a potential revenue stream for ValiRx.
"This first sale of our new product range is a major milestone for our commercialisation efforts," said chief executive officer Mark Eccleston.
At 1158 GMT, shares in ValiRx were up 23.13% at 1.69p.
Reporting by Josh White for Sharecast.com.
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.
